• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers develop cargo-carrying red blood cells to improve MS and T1D in mice

March 7, 2017 By Sarah Faulkner

Researchers develop cargo-carrying red blood cells to improve MS and T1D in miceResearchers from the Whitehead Institute for Biomedical Research modified red blood cells with disease-specific antigens to prevent and alleviate multiple sclerosis and Type I diabetes in early stage mouse models. The team’s work was published this week in PNAS. 

Conventional therapies for autoimmune diseases include immunosuppressants, but these drugs can desensitize the immune system’s response to pathogens. Instead, the team of researchers employed red blood cells tagged with antibodies to train the immune system to ignore antigens that cause the body to attack itself.

“This is a very promising step in the development of therapies for autoimmune diseases,” lead researcher Harvey Lodish said in prepared remarks. “If this type of response is also true in humans, then it could make a lot of these therapies possible for these diseases and similar conditions.”

Red blood cells can quickly access tissue and they are recycled every month in mice and every 4 months in humans.

In this experiment, the team drew blood from a mouse and tagged red blood cells with the antigens that trigger the harmful immune response. They then transfused the manipulated red blood cells back into mouse models of T1D and MS – the entire process takes 1 hour, the researchers reported.

The transfusions reduced the disease’s symptoms and a single injection prior to the onset of disease prevented further symptoms, according to the team.

“Essentially what we’re doing is hijacking the red blood cell clearance pathway, such that the foreign antigen masquerades as the red blood cells’ own, such that these antigens are being tolerated in the process,” 1st author Novalia Pishesha explained.

Filed Under: Diabetes, Featured, Immunotherapy, Research & Development Tagged With: Whitehead Institute for Biomedical Research

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS